Drug Profile


Alternative Names: AEVI-001; LAM 105; MDGN-001; NFC-1; NS 105

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Nippon Shinyaku
  • Developer Aevi Genomic Medicine
  • Class Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Cholinergic receptor agonists; GABA B receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Attention-deficit hyperactivity disorder
  • Phase II Di George syndrome
  • Discontinued Cognition disorders; Major depressive disorder

Most Recent Events

  • 20 Mar 2017 Safety and efficacy results from the phase-II/III SAGA trial in Attention-deficit hyperactivity disorder released by Aevi Genomic Medicine
  • 17 Feb 2017 Aevi Genomic Medicine completes the phase-II/III SAGA trial in Attention-deficit hyperactivity disorder (In adolescents) in USA (PO) (NCT02777931)
  • 09 Jan 2017 Phase-II clinical trials in Di-George syndrome (In adolescents) in USA (PO) (Aevi Genomic Medicine's pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top